Equillium Q4 2024 Earnings Report

Equillium EPS Results

• Actual EPS: -$0.16
• Consensus EPS: -$0.22
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Equillium Revenue Results

• Actual Revenue: $4.39 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Equillium Announcement Details

• Quarter: Q4 2024
• Date: 3/27/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, March 27, 2025
• Conference Call Time: 7:00AM ET

Equillium (NASDAQ:EQ) (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies. The company has since advanced EQ001 through Phase 1 and Phase 2 clinical trials, evaluating its potential in steroid-refractory acute GVHD and exploring additional autoimmune indications, such as ulcerative colitis. Equillium’s R&D strategy emphasizes rigorous clinical development and targeted patient populations to address areas of high unmet medical need.

Equillium conducts its clinical trials and research activities primarily in the United States, collaborating with leading academic institutions and transplant centers. The company’s global development plan includes potential partnerships or licensing arrangements to expand access to its therapies beyond North America. Equillium maintains a focused corporate structure designed to streamline decision-making and support efficient execution of its clinical programs.

Under the leadership of President and Chief Executive Officer Roger Pomerantz, Equillium has built a management team with deep expertise in immunology, clinical development, and regulatory affairs. The company’s board and scientific advisory committee include seasoned industry professionals who guide Equillium’s strategic direction. As a clinical-stage enterprise, Equillium remains committed to advancing its immunotherapy candidates through pivotal trials and towards regulatory approval for patients in need.